Enhancing the efficacy and persistence of adoptive T cell therapies

Ref No: Joh-3155 & Joh-3733-19

 

Apollo Therapeutics, working closely with Prof. Randall Johnson and his team in the Department of Physiology, Development & Neuroscience at the University of Cambridge have developed a small molecule that promotes memory T cell populations – octyl S-2-hydroxyglutarate – and have demonstrated applicability to human CAR-T systems.

 

Licensing opportunity: octyl S-2-hydroxyglutarate

  • Promotes memory T cell populations, conferring persistence and proliferation that translates into enhanced anti-tumour efficacy
  • Characterised in mouse and human systems
  • Fully compatible with human CAR-T lentiviral transduction protocols
  • Opportunity for clinical differentiation

 

Download more information

Make an Enquiryread more arrow

Enquiry for Enhancing the efficacy and persistence of adoptive T cell therapies

Available Technologies Enquiry

To find out more about how this website collects your personal data see www.enterprise.cam.ac.uk/about-us/information-compliance/data-protection/core-privacy-notices/website-users-use-personal-information/
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.

Tags: , , ,